Core Insights - The light medical beauty market in China has surpassed half of the overall medical beauty market, becoming the mainstream beauty method by 2024, with significant contributions from non-invasive and minimally invasive procedures [1][2] Market Overview - Light medical beauty is defined as professional medical beauty projects that fall between surgical procedures and lifestyle beauty, utilizing non-invasive or minimally invasive methods for skin management, contour modification, and anti-aging effects [1] - The rapid growth of the light medical beauty market is attributed to its advantages such as minimal trauma, quick recovery, significant results, and relatively low risks, aligning with modern consumers' dual demands for beauty and quality of life [2] Consumer Trends - The penetration rate of the light medical beauty market is increasing, with 34% of consumers planning to engage in light medical beauty services in the coming year, marking a 36% increase from the previous year [4] - Among the interested consumer group, over one-third are new entrants, injecting fresh growth vitality into the Chinese medical beauty industry [4] Popular Products - Injectable and photothermal products are the main attractions for light medical beauty consumers, with ultrasound-based products (e.g., ultrasound scalpel) rapidly gaining popularity [5] Consumption Behavior - Consumers are increasingly rational in their light medical beauty choices, prioritizing needs-based combinations of projects and products, with over half selecting options based on specific needs [7] - The average planned consumption has increased to 2.4 projects per consumer, reflecting a 14% year-on-year growth [7] Consumer Demographics - The consumer base for light medical beauty exhibits high retention and strong growth, with seasoned consumers making up 35% of the existing market, indicating their essential role in the market [10] - Among the new consumer group, high-end novices represent 38%, characterized by high standards for beauty and a willingness to pay, with a focus on facial anti-aging solutions [10]

公司公告汇总 上海昊海生物科技股份有限公司发布关于2024年年度权益分派实施后调整回购A股股份价格上限的公 告。公司以集中竞价交易方式回购A股股份价格上限由不超过89.31元/股调整为88.72元/股，调整起始日 为2025年6月30日。公司于2024年8月16日召开董事会审议通过回购方案，回购资金总额不低于10,000.00 万元且不超过20,000.00万元，回购期限为12个月。2024年半年度权益分派实施后，回购价格上限曾调整 为不超过89.31元/股。2025年3月21日和6月10日召开的董事会及股东周年大会审议通过2024年度利润分 配预案，向全体股东每10股派发现金红利6.00元。本次权益分派A股股权登记日为2025年6月27日，除权 除息日为2025年6月30日。根据相关规定，公司对回购价格上限进行相应调整。调整后的回购价格上限 计算为88.72元/股。本次回购资金总额不变，按新价格上限测算，回购股份数量约为112.7142万股至 225.4283万股，占公司总股本比例约为0.48%至0.97%。公司将根据市场情况择机实施回购并履行信息披 露义务。 上海昊海生物科技股份有限公司发布关于第二期以集 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年7月4日 I. 法定/註冊股本變動 證券代號 (如上市) 06826 說明 H股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 39,141,840 RMB 1 RMB 39,141,840 增加 / 減少 (-) 0 RMB 本月底結存 39,141,840 RMB 1 RMB 39,141,840 證券代號 (如上市) N/A 說明 A股（上海證券交易所科創板，股份代號：688366） 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 194,051,855 RMB 1 RMB 194,051,855 增加 / 減少 (-) 0 RMB 0 本月底結存 194,051,855 RMB 1 RMB 194,051,855 本月底法定/註冊股本總額： RMB 233,193,695 備註： 第 1 頁 共 1 ...

致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 呈交日期: 2025年7月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 39,141,840 | RMB | | 1 | RMB | | 39,141,840 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | | | 本月底結存 | | | 39,141,840 | RMB | | 1 | R ...

Group 1 - The majority of consumers in the medical beauty market spend between 10,000 to 50,000 yuan annually, indicating a diverse range of services from basic skincare to moderately complex cosmetic procedures [1] - First-tier cities dominate the medical beauty consumption market, accounting for approximately 69% of total spending, driven by concentrated medical resources and advanced consumer capabilities [3] - The average age of consumers in the medical beauty sector is around 35 years, with over 72% of high-end consumers aged 30 and above, reflecting a mature and stable consumption mindset [5][7] Group 2 - There is a notable increase in male consumers seeking medical beauty services, with 43% planning to increase their spending in this area, highlighting a shift in self-image management among men [7][8] - The demand for outbound medical beauty services is rising, particularly in Japan and South Korea, with about 31% of middle to high-income consumers planning to seek these services abroad in 2024 [10]

Core Viewpoint - The strategic partnership between China Resources Pharmaceutical and Haohai Biological Technology marks a significant move into the medical aesthetics sector, leveraging each company's strengths to enhance market presence and product offerings [1][2][4]. Group 1: Partnership Details - The collaboration aims to establish a comprehensive "R&D-Production-Channel" cooperation system, integrating China Resources' extensive OTC network across 28 provincial regions with Haohai's industrial base advantages [1][2]. - Haohai Biological, recognized as one of the "three giants" in medical aesthetics, reported a gross margin of 77.47% for its medical aesthetic products last year, highlighting the profitability of this sector [1][4]. - The partnership is expected to facilitate Haohai's expansion into second- and third-tier markets, utilizing China Resources' established distribution channels [2][4]. Group 2: Market Context - The Chinese medical aesthetics market is projected to grow from 189.2 billion yuan in 2021 to 410.8 billion yuan by 2025, with a compound annual growth rate (CAGR) exceeding 17% [6][8]. - Non-surgical aesthetic procedures are anticipated to grow at a rate of over 15% annually, indicating a robust demand for these services [1][6]. - The entry of traditional pharmaceutical giants into the medical aesthetics space is accelerating, with companies like Sinopharm and Shanghai Pharmaceuticals expanding their presence through various strategies [6][8]. Group 3: Financial Implications - Haohai's revenue from medical aesthetics and wound care products is expected to reach 1.195 billion yuan in 2024, accounting for 44.38% of its total revenue, with hyaluronic acid products contributing 742 million yuan [3][4]. - The collaboration is anticipated to optimize cost structures, allowing Haohai to reduce its R&D expenses by 25.40% in the first quarter of 2025, as it will no longer need to invest heavily in building its own sales team [4][6]. Group 4: Industry Trends - The medical aesthetics industry is witnessing a shift towards brand consolidation and standardization, driven by stricter regulations and evolving consumer preferences [7][8]. - The consumer demographic is diversifying, with an increasing proportion of male and older consumers, leading to a broader range of aesthetic service offerings [7][8]. - The partnership between China Resources and Haohai is seen as a new model for upstream and downstream collaboration in the medical aesthetics industry, potentially driving the sector towards a more clustered and standardized future [7][8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期以集中競價交易方式回購公司A股股份的進展公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年7月2日 * 僅供識別 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 证券代码：688366 证券 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-034 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 书》（公告编号：2024-042）。 公司 A 股 2024 年半年度权益分派实施完毕后，本次以集中竞价交易方式回购 公司 A 股股份价格上限由不超过 89.71 元/股（含），调整为不超过 89.31 元/股（含）。 具体内容详见公司于 2024 年 10 月 11 日在上海证券交易所网站（www.sse.com.cn） 披露的《上海昊海生物科技股份有限公司关于 2024 年半年度权益分派实施后调整 回购 A 股股份价格上限的公告》（公告编号：2024-056）。 公司 A 股 2024 年年度权益分派实施完毕后，本次以集中竞价交易方式回购公 司 A 股股份价格上限由不超过 89.31 元/股（含），调整为不超过 88.72 元/股（含）。 具体内容详见公司于 2025 年 7 月 1 日在上海证券交易所网站（ww ...

Industry Overview - The medical beauty injection products mainly include hyaluronic acid, collagen, regenerative materials, and botulinum toxin, with hyaluronic acid and collagen being classified as medical devices, while botulinum toxin is categorized as a toxic medical drug [1][2][5] Industry Chain Analysis - The upstream of the medical beauty injection materials includes raw materials and equipment manufacturing, while the midstream focuses on product research and manufacturing, and the downstream consists of sales channels such as public hospitals and private chains [2][5] Industry Development History - The Chinese medical beauty injection materials market has evolved from reliance on imports to self-innovation, with significant milestones including the approval of the first domestic hyaluronic acid filler in 2009 and the emergence of domestic leaders like Huaxi Biological, Aimeike, and Haohai Biological by 2015 [6][8] Industry Policy Background - Regulatory measures have been strengthened since 2019, with guidelines issued for the clinical trial of hyaluronic acid products and stricter management of medical beauty injection materials to enhance product quality and safety [9][11][12] Current Industry Status - The market size of China's medical beauty injection materials is projected to reach approximately 34.6 billion yuan in 2024, reflecting a year-on-year growth of 28.6% and a CAGR of 31.3% from 2021 to 2024 [14][16] Market Structure - Hyaluronic acid and botulinum toxin dominate the market, with hyaluronic acid accounting for about 36% and botulinum toxin for about 29% of the total market share [17][19] Competitive Landscape - Major competitors in the hyaluronic acid market include Huaxi Biological, Aimeike, and Haohai Biological, while the botulinum toxin market is primarily represented by Lanzhou Biological, which is currently the only domestic company with approved products [23][25] Future Industry Outlook - The medical beauty injection materials market is expected to reach 93.7 billion yuan by 2030, driven by technological advancements, compliance, and the rise of male consumers [28][30] Industry Development Trends - Key trends include the long-lasting and precise application of materials, the rise of intelligent and customized solutions, and increased regulatory scrutiny leading to higher approval thresholds for injection materials [32]

Industry Overview - The medical beauty industry is under strict government regulation, with a series of targeted policies aimed at ensuring safe and reliable medical services for consumers [1][2][3] - Key companies in the industry include Aimeike (300896), Haohai Biological (688366), Huaxi Biological (688363), Aoyuan Meigu (000615), Huadong Pharmaceutical (000963), Langzi Co., Ltd. (002612), and Huahan Plastic Surgery (430335) [1] Policy Direction - The government has implemented comprehensive management measures covering operational standards for medical beauty institutions, including establishment criteria, personnel requirements, and equipment maintenance [1] - Enhanced regulatory measures include establishing supervision mechanisms, increasing enforcement checks, and raising penalties for violations [1][2] Market Development - The "China City Medical Beauty Industry Development Index (2024)" indicates that cities like Beijing, Shenzhen, Chengdu, Guangzhou, Shanghai, Jinan, Changsha, Ningbo, Hangzhou, and Chongqing are leading in medical beauty industry performance [4] - Notably, Ningbo has risen from 23rd to 8th place, benefiting from its "246" trillion-level industrial cluster planning, which emphasizes biomedicine [4] Global Trends - According to ISAPS, the total number of surgical and non-surgical procedures globally increased by 3.4% in 2023, reaching 34.9 million procedures [5] - The United States remains the leader in plastic surgery, performing over 6.1 million procedures in 2023, followed by Brazil with 3.3 million [10]